Medical

How ketamine relieves depression by suppressing the brain's "anti-reward" center

How ketamine relieves depression by suppressing the brain's "anti-reward" center
A breakthrough study has revealed the potential mechanism behind how ketamine rapidly relieves symptoms of depression
A breakthrough study has revealed the potential mechanism behind how ketamine rapidly relieves symptoms of depression
View 1 Image
A breakthrough study has revealed the potential mechanism behind how ketamine rapidly relieves symptoms of depression
1/1
A breakthrough study has revealed the potential mechanism behind how ketamine rapidly relieves symptoms of depression

The anti-depressant qualities of ketamine, initially developed as an anesthetic before drifting into recreational circles due to its hallucinogenic properties, have been a booming topic of research over the past few years. Anecdotal evidence of the drug's effects have been so strong that "ketamine clinics" have popped up all over the US, delivering experimental treatments to patients for hundreds of dollars a dose. Researchers at Zhejiang University in China have now uncovered exciting new insights into a mechanism that may finally explain how ketamine has such a rapid anti-depressant effect.

Research from Columbia University Medical Center has recently clinically verified the drug's ability to rapidly reduce major depressive symptoms in a matter of hours, but the actual mechanism underlying these effects has been unclear. It's been known for some time that ketamine blocks a protein receptor in the brain called N-methyl-D-aspartate (NMDA), and it is this process that some have suspected is the cause of the drug's fast-acting anti-depressant qualities. But until now it hasn't been clear where in the brain this process is occurring.

The new research focused on a very small area deep in the center of the brain called the lateral habenula. This area is commonly referred to by researchers as the "anti-reward center," as it's known for suppressing nearby reward areas of the brain that release dopamine and serotonin. Following growing evidence suggesting that overactivity in the lateral habenula is related to depression, the researchers examined how ketamine directly affects activity in that region of the brain.

Using rodent models, they found that certain patterns of rapid bursts of neuronal activity in the lateral habenula resulted in major depressive behavior in the animals. This correlation was verified by genetically engineering rats to enhance this particular type of brain activity, confirming that it did indeed promote symptoms of depression. The next part of the research revealed that this particular bursting neuronal activity in the lateral habenula was dependent on NMDA receptors, and knowing that ketamine was an NMDA receptor blocker led the researchers to examine if this could be the elusive mechanism behind the drug's rapid anti-depressant effects.

Administering ketamine directly into the lateral habenula of rats resulted in a very quick reversal of depression-like behaviors in the animals. A second experiment using a more specific NMDA receptor antagonist achieved the same reduction in burst activity and associated anti-depressant effects, suggesting that this is the probable mechanism behind ketamine's rapid positive effects.

The researchers do note that while this study addresses the rapid effects of ketamine, it doesn't account for the long-term anti-depressant qualities of the drug. However, suppressing burst activity in the lateral habenula does look like a promising area for new antidepressant research. A second accompanying research paper from the same team examined what could be causing this overactivity in the lateral habenula and suggests a potential protein target that could be manipulated to block it.

While there is a growing amount of research into the use of ketamine for depression, the drug's strong psychoactive effect and potential for abuse will certainly limit its widespread application. This research into how ketamine works on the brain will hopefully direct scientists toward the development of new ketamine-inspired drugs that target these same brain areas without the other negative psychoactive effects.

The study was published in the journal Nature.

1 comment
1 comment
Wombat56
I'm curious. How do the the various doses of ketamine compare for the different functions? For example, the dosages required to provide anesthesia, short and long term depression relief, and psychedelic experiences (which may be necessary for effective PTSD treatment)? For depression, do they take the drug on a continuing daily basis?